Why a Fractional AI Partner Beats Building an Internal AI Team

Every biotech CEO eventually asks the same question: should we build our own AI capability in-house, or find an external partner?

The answer depends on your stage, your headcount, and how fast the AI landscape is moving. For most clinical-stage biotechs under 200 employees, the math strongly favors a fractional AI operating partner.

The Real Cost of Building In-House

To build a credible internal AI capability, you need at minimum:

Head of AI / VP Data Science: $300-450K total comp
2-3 ML Engineers: $200-350K each
1-2 Data Engineers: $180-280K each
AI Product Manager: $200-300K

That's $2.5-4M per year in fully loaded costs — before you've deployed a single agent or automated a single workflow. And it takes 6-12 months just to hire the team, because senior AI talent is scarce and often reluctant to join companies under 200 people.

Then add the key-person risk. When your Head of AI leaves — and in this market, they will — you're rebuilding from scratch. Each functional area reinvents the wheel. There's no playbook.

What a Fractional AI Partner Provides

A fractional AI operating partner like HaiPhai provides the same capability at a fraction of the cost:

Available now, not in six months. We're live in weeks. Your first AI deployments are running before an in-house team would have finished interviewing candidates.

Cross-client playbooks. We've deployed AI across multiple biotech organizations. Each engagement makes the next one faster. Your internal team starts from zero every time.

Full value chain coverage. We operate across every function — R&D, Clinical, Regulatory, Finance, Legal, HR, BD, Commercial. An internal team typically covers one or two areas before running out of bandwidth.

Vendor-neutral. We evaluate tools and platforms based on what works for your specific needs, not based on what your AI team happens to know. Build vs. buy decisions are driven by outcomes, not internal skillsets.

De-risked by design. Our augment-not-replace posture means we're enhancing your existing team's output, not creating dependencies on AI systems that require specialized maintenance.

The Operating Model

The fractional model works because AI augmentation is not a one-time project — it's an ongoing operating capability. New models ship quarterly. New integration surfaces open. Your company's needs evolve as programs advance and teams grow.

A monthly retainer ensures you always have AI engineering and strategic capacity on call:

Monthly: Priority planning, build-and-deploy sprints, operating reports
Quarterly: Business impact reviews, AI roadmap updates, scope adjustments
Continuously: Agent monitoring, model upgrades, context engineering updates

New workstreams get added as opportunities arise — no separate SOW required for work within retainer scope.

When In-House Makes Sense

To be clear, there are scenarios where building internally is the right call:

You have 500+ employees and enough functional breadth to keep a full AI team busy
AI is your product — you're building AI-powered therapeutics or AI-native drug discovery tools
You've already deployed with a partner and want to bring mature, stable capabilities in-house

For most clinical-stage biotechs, the path is: partner first, build internal capability on top of a working foundation, and transition to in-house only when the volume justifies the fixed cost.

The Bottom Line

You don't need to hire an AI department to become an AI-native company. You need a partner who embeds alongside your team, proves value with hands-on executive education, trains your organization, and then operates AI across your business — with the capability compounding every month.

That's what HaiPhai's three-phase engagement model delivers. Education first, then training and configuration, then an ongoing operating partnership.

The AI landscape moves too fast to wait six months while you build a team. Start now, start fractional, and scale from there.